Dang, have you done much analysis on mining companies in a growth phase ?
There is probably some better comparisons to be made there, drugs are money up front, returns later, so when equity has doubled in a a bit over year with the acquisition obviously ROE is going to look bad for a while until all gains are achieved.
Part of the government approval of the acquisition involved guarantee of supply of the drugs, and AFAIK Mayne hasnt taken over all of it yet, and a lot is manufactured by third parties. And a couple of products havent even been launched yet. So its reasonable to assume ROE will improve.
MYX Price at posting:
94.5¢ Sentiment: Buy Disclosure: Held
